Uncertainty and sensitivity analyses of a decision analytic model for posteradication polio risk management

Risk Analysis

Volumn 28, Issue 4, 2008, Pages 855-876

  Duintjer Tebbens, Radboud J ^a   Pallansch, Mark A ^b   Kew, Olen M ^b   Sutter, Roland W ^c   Bruce Aylward, R ^c   Watkins, Margaret ^b   Gary, Howard ^b   Alexander, James ^b   Jafari, Hamid ^c   Cochi, Stephen L ^b   Thompson, Kimberly M ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Decision analysis; Polio eradication; Risk management; Sensitivity analysis; Uncertainty analysis

Indexed keywords

CHLORINE COMPOUNDS; FINANCE; INSURANCE; MANAGEMENT; PUBLIC POLICY; RISK ANALYSIS; RISK MANAGEMENT; RISK PERCEPTION; SENSITIVITY ANALYSIS; UNCERTAINTY ANALYSIS;

ANALYTIC MODELING; DECISION ANALYSIS; DECISION ANALYTIC MODELING; DYNAMIC COMPLEXITIES; FINAL COSTS; INCOME GROUPS; INFLUENCE DIAGRAMS; INPUT UNCERTAINTY; KNOWLEDGE GAPS; MANAGEMENT POLICIES; MODEL OUTPUTS; POLICY IMPLICATIONS; POLICY-MAKERS; POLIO ERADICATION; POLIOVIRUSES; SOURCES OF UNCERTAINTY; VARIATIONS OF;

PROBABILITY DISTRIBUTIONS;

ORAL POLIOMYELITIS VACCINE;

COST-BENEFIT ANALYSIS; DECISION ANALYSIS; DISEASE CONTROL; HEALTH POLICY; HEALTH RISK; MODELING; POLICY MAKING; SENSITIVITY ANALYSIS; UNCERTAINTY ANALYSIS; VIRUS;

ANALYTIC METHOD; ARTICLE; COST BENEFIT ANALYSIS; DECISION MAKING; HEALTH SURVEY; HUMAN; IMMUNIZATION; MANAGEMENT; POLIOMYELITIS; POLIOMYELITIS VIRUS; RISK MANAGEMENT; SENSITIVITY ANALYSIS; SOCIAL STATUS; UNCERTAINTY;

DECISION SUPPORT TECHNIQUES; HUMANS; MODELS, THEORETICAL; POLIOMYELITIS; RISK MANAGEMENT; UNCERTAINTY; WORLD HEALTH ORGANIZATION;

EID: 46749103521     PISSN: 02724332     EISSN: 15396924     Source Type: Journal    
DOI: 10.1111/j.1539-6924.2008.01078.x     Document Type: Article

References (39)

1. World Health Organization 2006). Global Polio Eradication Initiative Polio Case Count. Available at http://www.polioeradication.org/casecount.asp. Accessed April 24, 2008.
2. Sangrujee, N., Duintjer Tebbens, R. J., Cáceres, V. M., & Thompson, K. M. (2003). Policy decision options during the first 5 years following certification of polio eradication. Medscape General Medicine, 5 (4 35.
3. Thompson, K. M., Duintjer Tebbens, R. J., Pallansch, M. A., Kew, O. M., Sutter, R. W., Aylward, R. B., Watkins, M., Gary, H. E. Jr., Alexander, J. P. Jr., Jafari, H., & Cochi, S. L. (2008). The risks, costs, and benefits of global policies for managing polio after eradication (in press). American Journal of Public Health, 98 (7 1322 1330.
4. Duintjer Tebbens, R. J., Pallansch, M. A., Kew, O. M., Cáceres, V. M., Jafari, H., Cochi, S. L., Aylward, R. B., & Thompson, K. M. (2006). Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Analysis, 26 (6 1471 1505.
5. Duintjer Tebbens, R. J., Sangrujee, N., & Thompson, K. M. (2006). The costs of polio risk management policies after eradication. Risk Analysis, 26 (6 1507 1531.
6. Duintjer Tebbens, R. J., Pallansch, M. A., Kew, O. M., Cáceres, V. M., Sutter, R. W., & Thompson, K. M. (2005). A dynamic model of poliomyelitis outbreaks: Learning from the past to help inform the future. American Journal of Epidemiology, 162 (4 358 372.
7. Thompson, K. M., & Graham, J. D. (1996). Going beyond the single number: Using probabilistic risk assessment to improve risk management. Human and Ecological Risk Assessment, 2 (4 1008 1034.
8. Duintjer Tebbens, R. J., Thompson, K. M., Hunink, M., Mazzuchi, T. M., Lewandowski, D., Kurowicka, D., & Cooke, R. M. (2008). Uncertainty and sensitivity analyses of a dynamic economic evaluation model for vaccination programs. Medical Decision Making, 28 (2 182 200.
9. World Health Organization 2004). Conclusions and recommendations of the ad hoc advisory committee on poliomyelitis eradication, Geneva, 21-22 September 2004. Weekly Epidemiological Record, 79 (45 401 408.
10. World Health Organization 2004). Global Polio Eradication Initiative: Strategic Plan 2004-2008. Geneva.
11. Bureau of Labor Statistics, U.S. Department of Labor 2002). Consumer Price Index. Available at ftp://ftp.bls.gov/pub/special.requests/cpi/cpiai.txt. Accessed July 6, 2006.
12. Gold, M. R., Siegel, J. E., Russel, L. B., & Weinstein, M. C. (1996). Cost-Effectiveness in Health and Medicine. New York : Oxford University Press.
13. World Bank 2002). World Bank List of Economies (July 2002). Available at http://www.csirwebistad.org/pdf/classi.pdf. Accessed January 23, 2008.
14. Hull, B. P., & Dowdle, W. R. (1997). Poliovirus surveillance: Building the global polio laboratory network. Journal of Infectious Diseases, 175 (Suppl. 1 S113 S116.
15. World Health Organization 2005). Advisory committee on polio eradication - Standing recommendations for responding to circulating polioviruses in polio-free areas. Weekly Epidemiological Record, 23 (38 330 331.
16. Thompson, K. M., Duintjer Tebbens, R. J., & Pallansch, M. A. (2006). Evaluation of response scenarios to potential polio outbreaks using mathematical models. Risk Analysis, 26 (6 1541 1556.
17. World Health Organization 2004). WHO Global Action Plan for Laboratory Containment of Wild Polioviruses, 2nd ed. Geneva : World Health Organization. 2004 January. Report No.: WHO/V&B/03.11.
18. Global Alliance for Vaccines and Immunization 2005). Investment Case for the Polio Stockpile. Available at http://www.vaccinealliance.org/resources/ 16brd_07._Polio_Stockpile_investment_case.pdf. Accessed January 7, 2006.
19. de Gourville, E. M., Sangrujee, N., Duintjer Tebbens, R. J., Pallansch, M. A., & Thompson, K. M. (2006). Global surveillance and the value of information: The case of the global polio laboratory network. Risk Analysis, 26 (6 1557 1569.
20. Pinheiro, F. P., Kew, O. M., Hatch, M. H., da Silveira, C. M., & de Quadros, C. A. (1997). Eradication of wild poliovirus from the Americas: Wild poliovirus surveillance - Laboratory issues. Journal of Infectious Diseases, 175 (Suppl. 1 S43 S49.
21. World Health Organization 2006). Inactivated poliovirus vaccine following oral poliovirus cessation. Supplement to the WHO position paper. Weekly Epidemiological Record, 81, 137 144.
22. World Health Organization 2003). Introduction of inactivated poliovirus vaccine into oral poliovirus vaccine-using countries. WHO position paper. Weekly Epidemiological Record, 78, 241 250.
23. UN Population Division. (2003). World Population Prospects Population Database: The 2002 Revision Population Database. Available at http://esa.un.org/unpp/index.asp?panel=2. Accessed July 31, 2003.
24. UNICEF 2003). The State of the World' Children 2003. Available at http://www.unicef.org/sowc03. Accessed January 23, 2008.
25. Sutter, R. W., Cáceres, V. M., & Más Lago, P. (2004). The role of routine immunization in the post-certification era. Bulletin of the World Health Organization, 82 (1 31 38.
26. Murray, C. J., & Lopez, A. D. (1996). The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge, MA : Harvard University Press.
27. Musgrove, P. (1988). Is polio eradication in the Americas economically justified? Bulletin of the Pan American Health Organization, 22 (1 1 16.
28. Ministry of Health, Brazil 1982). Memória Sobre Estimativa de Custos dos Casos de Poliomielite no Brasil Em. Brasilia, Brazil.
29. Miller, M. A., Sutter, R. W., Strebel, P. M., & Hadler, S. C. (1996). Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule. Journal of the American Medical Association, 276 (12 967 971.
30. Bart, K., Foulds, J., & Patriarca, P. (1996). Global eradication of poliomyelitis: Benefit-cost analysis. Bulletin of the World Health Organization, 74, 35 45.
31. Hatzandrieu, E. J., Palmer, C. S., & Halpern, M. T. (1994). A Cost Benefit Analysis of the OPV Vaccine. Atlanta, Batelle : Centers for Disease Control and Prevention.
32. Hutubessy, R., Chisholm, D., & Edejer, TT-T, WHO-CHOICE 2003). Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Effectiveness and Resource Allocation, 1 (1 8.
33. World Bank 2006). World Development Indicators Data Query. World Bank. Available at http://devdata.worldbank.org/data-query/. Accessed May 8, 2006.
34. Saltelli, A., Tarantola, S., Campolongo, F., & Ratto, M. (2004). Sensitivity Analysis in Practice: A Guide to Assessing Scientific Models. Chichester, UK : John Wiley and Sons.
35. Lewandowski, D., Cooke, R. M., & Duintjer, Tebbens, R. J. (2007). Sample-based estimation of correlation ratio with polynomial approximation (in press). Transactions on Modeling and Computer Simulation, 18 (1 Article 3 : 1 17.
36. World Health Organization 2005). Immunization Financing. Immunization, Vaccines and Biologicals. Available at http://www.who.int/ immunization_financing/en/. Accessed March 8, 2005.
37. Cooke, R. M. (1991). Experts in Uncertainty: Opinion and Subjective Probability in Science. New York. Oxford University Press 2007). Global update on vaccine-derived polioviruses, January 2006-August 2007. Weekly Epidemiological Record, 82 (39 337 344.
38. Eichner, M., & Dietz, K. (1996). Eradication of poliomyelitis: When can one be sure that polio virus transmission has been terminated? American Journal of Epidemiology, 143 (8 816 822.
39. World Health Organization 2005). Progress towards poliomyelitis eradication-poliomyelitis outbreak in Sudan, 2004. Weekly Epidemiological Record, 80 (5 42 46.